Re: Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

被引：2
作者：
Taneja, Samir S.
机构：
来源：
JOURNAL OF UROLOGY | 2020年 / 203卷 / 01期
关键词：
D O I：
10.1097/01.JU.0000611504.41578.ee
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：32 / 33
页数：2
相关论文
共 2 条
  • [1] Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens
    Crawford, E. David
    Schellhammer, Paul F.
    McLeod, David G.
    Moul, Judd W.
    Higano, Celestia S.
    Shore, Neal
    Denis, Louis
    Iversen, Peter
    Eisenberger, Mario A.
    Labrie, Fernand
    [J]. JOURNAL OF UROLOGY, 2018, 200 (05) : 956 - 966
  • [2] Long-Term Antitumor Activity and Safety of Enzalutamide Monotherapy in Hormone Naive Prostate Cancer: 3-Year Open Label Followup Results
    Tombal, Bertrand
    Borre, Michael
    Rathenborg, Per
    Werbrouck, Patrick
    Van Poppel, Hendrik
    Heidenreich, Axel
    Iversen, Peter
    Braeckman, Johan
    Heracek, Jiri
    Baron, Benoit
    Krivoshik, Andrew
    Section, Mohammad Hirmand
    Smith, Matthew R.
    [J]. JOURNAL OF UROLOGY, 2018, 199 (02) : 459 - 464
1